research 701 Rethinking alopecia scores: Correlating measures of hair loss with established photographic scoring systems
The conclusion suggests that a new system for measuring hair loss could be created using automated analysis of photographs.
Search
for
Sort by
Research
30 / 1000+ results 
research Spironolactone in dermatology: uses in acne and beyond
Spironolactone is a low-cost, effective, and generally safe treatment for various skin conditions related to hormones.
research 451 Spironolactone for treatment of concomitant female pattern hair loss in scarring alopecia patients
Spironolactone safely and effectively treats hair loss in female scarring alopecia patients.
research Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review and meta-analysis comparing topical and oral minoxidil for treating androgenetic alopecia
Oral minoxidil is an effective alternative for hair loss but may cause more unwanted hair growth.
research Alopecia areata incognita: clinical characteristics and use of the Sinclair shedding scale
The Sinclair Shedding Scale is effective for diagnosing Alopecia Areata Incognita and monitoring treatment success.
research Raw data collected during the study.
Oral minoxidil reduced hair shedding in women with chronic telogen effluvium.
research Referee report. For: Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study [version 1; referees: 1 approved]
Oral minoxidil effectively reduces hair shedding in women with chronic telogen effluvium.
research Association Between LDL-C and Androgenetic Alopecia Among Female Patients in a Specialty Alopecia Clinic
Higher bad cholesterol levels are linked to more severe female pattern hair loss.
research 503 Use of low-dose spironolactone in female pattern hair loss in a specialty alopecia clinic
Low-dose spironolactone effectively treats female pattern hair loss with mild side effects.
![Minoxidil and Its Use in Hair Disorders: A Review [Corrigendum]](/images/research/d5b5fb1b-96a4-4e61-a554-3fe9a1f78497/small/11472.jpg)
research Minoxidil and Its Use in Hair Disorders: A Review [Corrigendum]
Low-dose Minoxidil combined with Spironolactone helps reduce hair loss and improve hair density in women, with some mild side effects.
research Minoxidil and Its Use in Hair Disorders: A Review [Corrigendum]
Minoxidil 0.25 mg with spironolactone 25 mg reduces hair loss and improves hair density in women.
research Hair shedding in women: how much is too much?
The hair shedding scale accurately identifies abnormal hair shedding in women with long hair, with grades 5 and 6 indicating excessive shedding.
research Treatment of alopecia areata in pre‐adolescent children with oral tofacitinib: A retrospective study
Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
research 51297 Low dose oral minoxidil in COVID-19-associated telogen effluvium. A retrospective analysis of 69 patients.
Low-dose oral minoxidil helps hair regrowth in COVID-19-related hair loss with few side effects.
research Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial
The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
research SALT Score Cards: Facilitating SALT Score Calculation in Alopecia Areata
A new tool simplifies alopecia areata severity scoring but needs validation.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research High circulating oestrone and low testosterone correlate with adverse clinical outcomes in men with advanced liver disease
Men with advanced liver disease and high oestrone and low testosterone levels have worse health outcomes.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG)*
Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.
research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
research 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
research 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.